Literature DB >> 9403703

Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.

A P Dei Tos1, S Piccinin, C Doglioni, T Vukosavljevic, T Mentzel, M Boiocchi, C D Fletcher.   

Abstract

Myxoid and round cell liposarcoma represents a morphological spectrum in which tumor progression from low-grade myxoid to high-grade round cell areas is frequently observed. A distinctive t(12;16)(q13;p11) reciprocal translocation rearranges the CHOP gene localized to 12q13 in most cases. Data concerning the occurrence of cell cycle aberrations in this subset of mesenchymal malignancies are very limited. Therefore, we analyzed a histologically homogeneous series of 21 cases of myxoid and round cell liposarcoma. The p53 pathway was studied by investigating the TP53 gene and protein, mdm2 protein, and p21Waf1 protein. The Rb-cyclin D pathway was analyzed by studying the pRb protein, the p16MTS1 gene, cyclin D1, cyclin D3, p27Kip1, cdk4, and cdk6 proteins. In contrast with the rare involvement of the TP53 gene in well differentiated liposarcoma, aberrations of the TP53 gene were observed in approximately 30% of cases of myxoid and round cell liposarcoma. Notably, mdm2 overexpression was seen in 56% of cases and correlated with histological grade, therefore indicating a possible role in tumor progression. Abnormalities involving the Rb-cyclin D pathway were observed in more than 90% of cases. pRb loss was present in one-third of cases and, at variance with that observed in other subsets of sarcoma, overexpression of cyclin Ds represented a rare event. Interestingly, upregulation of either cdk4 or cdk6 was demonstrated in 85% of cases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403703      PMCID: PMC1858364     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.

Authors:  J Toguchida; T Yamaguchi; B Ritchie; R L Beauchamp; S H Dayton; G E Herrera; T Yamamuro; Y Kotoura; M S Sasaki; J B Little
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

2.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx.

Authors:  R Maestro; R Dolcetti; D Gasparotto; C Doglioni; S Pelucchi; L Barzan; E Grandi; M Boiocchi
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

3.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

4.  Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.

Authors:  M R Stratton; S Moss; W Warren; H Patterson; J Clark; C Fisher; C D Fletcher; A Ball; M Thomas; B A Gusterson
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

5.  Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.

Authors:  S Pilotti; G Della Torre; C Lavarino; S Di Palma; G Sozzi; F Minoletti; S Rao; G Pasquini; A Azzarelli; F Rilke; M A Pierotti
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

6.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.

Authors:  A Arnold; H G Kim; R D Gaz; R L Eddy; Y Fukushima; M G Byers; T B Shows; H M Kronenberg
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

7.  p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue.

Authors:  A P Dei Tos; C Doglioni; L Laurino; M Barbareschi; C D Fletcher
Journal:  Histopathology       Date:  1993-01       Impact factor: 5.087

8.  Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas.

Authors:  A De Chiara; A T'Ang; T J Triche
Journal:  J Natl Cancer Inst       Date:  1993-01-20       Impact factor: 13.506

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  p53 abnormalities in different subtypes of human sarcomas.

Authors:  A Andreassen; T Oyjord; E Hovig; R Holm; V A Flørenes; J M Nesland; O Myklebost; J Høie; O S Bruland; A L Børresen
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

View more
  10 in total

1.  Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

Authors:  Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah
Journal:  Lab Invest       Date:  2016-06-06       Impact factor: 5.662

2.  Myxoid liposarcoma with cartilaginous differentiation: a case study with cytogenetical analysis.

Authors:  Hyunchul Kim; Won Hwangbo; Sangjeong Ahn; Suhjin Kim; Insun Kim; Chul Hwan Kim
Journal:  Korean J Pathol       Date:  2013-06-25

3.  PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Authors:  Elizabeth Charytonowicz; Melissa Terry; Katherine Coakley; Leonid Telis; Fabrizio Remotti; Carlos Cordon-Cardo; Robert N Taub; Igor Matushansky
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  A case of myxoid liposarcoma of the breast.

Authors:  Tsuyoshi Saito; Misa Ryu; Yuki Fukumura; Miki Asahina; Atsushi Arakawa; Katsuya Nakai; Hiroyoshi Miura; Mitsue Saito; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 5.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

6.  Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma.

Authors:  U Tateishi; T Hasegawa; Y Beppu; A Kawai; N Moriyama
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

7.  Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.

Authors:  Cheng-Han Lee; Rola H Ali; Marjan Rouzbahman; Adrian Marino-Enriquez; Meijun Zhu; Xiangqian Guo; Alayne L Brunner; Sarah Chiang; Samuel Leung; Nataliya Nelnyk; David G Huntsman; C Blake Gilks; Torsten O Nielsen; Paola Dal Cin; Matt van de Rijn; Esther Oliva; Jonathan A Fletcher; Marisa R Nucci
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

8.  p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma.

Authors:  Radoslav Davidović; Jelena Sopta; Vesna Mandušić; Milena Krajnović; Maja Stanojević; Goran Tulić; Bogomir Dimitrijević
Journal:  Med Oncol       Date:  2013-08-06       Impact factor: 3.064

9.  Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Yuka Hotokebuchi; Takeaki Ishii; Akira Maekawa; Yuichi Yamada; Hidetaka Yamamoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  J Pathol Clin Res       Date:  2015-03-16

10.  Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.

Authors:  Michaela Angelika Ihle; Sebastian Huss; Wiebke Jeske; Wolfgang Hartmann; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Reinhard Büttner; Harri Sihto; Kirsten Sundby Hall; Mikael Eriksson; Peter Reichardt; Heikki Joensuu; Eva Wardelmann
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.